These are the stocks posting the largest moves before the bell.Market Insiderread more
Allergan shareholders will receive 0.8660 AbbVie shares and $120.30 in cash for each share held, for a total value of $188.24 per Allergan share.Biotech and Pharmaceuticalsread more
Amazon announces that Amazon Prime Day will last for two days, starting July 15.Technologyread more
Home prices in April were 3.5% higher than a year earlier, according to the S&P CoreLogic Case-Shiller U.S. National Home Price Index.Real Estateread more
Joe Biden could face some uncomfortable questions about his record on women this week at the first Democratic presidential debates in Miami.2020 Electionsread more
"What else do you have to do that will actually have to affect the Iranians' calculus?" said Amos Hochstein, who served as U.S. special envoy for international energy affairs...World Politicsread more
FedEx heads into Tuesday afternoon's earnings deep in a bear market. A failure to deliver could mark a massive buying opportunity.Trading Nationread more
Investors are piling into gold, sending the precious metal to a six-year high on Monday, and analysts think the commodity has established a base to go even higher.Marketsread more
Here are the biggest calls on Wall Street on TuesdayInvestingread more
Gold prices hit their highest level in six years on Tuesday as investors plowed into the precious metal amid the prospects of lower interest rates and tensions between Iran...Marketsread more
In a new interview with CBS's Gayle King, Adam Mosseri addressed a common suspicion about how Instagram targets ads.Technologyread more
Alphabet's Verily division has hired former FDA chief Dr. Robert Califf as an adviser, the company announced in a blog post Wednesday.
CNBC on Tuesday exclusively reported that the company was talking to Califf.
Califf will help oversee Project Baseline, a well-funded effort headed by fellow cardiologist Dr. Jessica Mega to study human health by tracking 10,000 people over at least four years. He will also continue to work at the Duke University Clinical Research Institute and have a new appointment as an adjunct professor in the Department of Medicine at Stanford. Duke and Stanford are teaming up with Verily for the baseline study.
The appointment of Califf is a big win for Verily, and couldn't come at a better time. The company just lost its top academic, former National Institute of Mental Health chief, Dr. Tom Insel.
Califf was nominated for the FDA role by President Barack Obama and stepped down in January, a standard procedure with a new administration. Shortly after stepping down, he spoke out in an interview about the antiquated ways in which companies collect medical data to test drugs and medical devices. He suggested that clinical trials should look more like A/B comparison tests routinely done by tech companies, such as Google.
It's not typical for health agency chiefs to join technology companies, but it might increasingly be an option as Silicon Valley starts moving into regulated industries. Verily works closely with life sciences companies including Dexcom, Sanofi and Johnson & Johnson on health hardware and software projects.